
A feature analyzing the recent investment activity in digital technologies and AI.
As healthcare systems undergo a digital transformation, the biopharma industry has begun to harness the power of new technologies such as artificial intelligence (AI) and digital tools, to improve research and development (R&D) and processes, and enhance stakeholder engagement to drive product adoption and revenue generation. Market researchers forecast that the pharma industry will spend up to $4.5 billion investing in the digital transformation of pharmaceutical manufacturing facilities by 2030 and spending on AI alone could exceed $3 billion by 2025 as companies use this technology to personalize treatment, facilitate data handling and analytics to generate actionable insights and drive outcome-based care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze